Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cenderitide · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Cenderitide | DRUG | Cenderitide is a dual receptor natriuretic peptide. |
| Placebo | DRUG | Placebo control |
Top 16 of 30 competitors
Cenderitide is being developed for the treatment of heart failure. It has been studied in patients with stable chronic heart failure, including a trial population that also had moderate renal impairment. It is an investigational therapy and has not been approved for commercial use.
Cenderitide is being developed by Capricor Therapeutics, Inc., which trades on the Nasdaq under the ticker CAPR. The company is the sponsor behind the clinical program evaluating the drug in heart failure.
Cenderitide is in Phase 2 clinical development for heart failure. Two trials have been completed, one Phase 2 study and one Phase 1/Phase 2 study, and there are currently no active trials listed for the program.
Cenderitide has been evaluated in two completed trials. NCT02359227 was a Phase 2 safety study in stable chronic heart failure with 14 participants. NCT02603614 was a Phase 1/Phase 2 safety study in chronic stable heart failure with moderate renal impairment and enrolled 8 participants.
Across the two completed Cenderitide trials, a total of 22 participants have been enrolled. NCT02359227 enrolled 14 patients with stable chronic heart failure, and NCT02603614 enrolled 8 patients with chronic stable heart failure and moderate renal impairment.
The completed Cenderitide trials were uncontrolled safety studies rather than randomized or double-blind trials. Both NCT02359227 and NCT02603614 were open-label studies designed to assess safety in patients with stable chronic heart failure.